To further explore these differences, we performed a quantitative analysis by SWATH-MS in which we identified 46 and 127 highly significant proteins differentially expressed in the preclinical and clinical stages of disease, respectively, compared to healthy controls.
← all excerpts
New preclinical biomarkers for prion diseases in the cerebrospinal fluid proteome revealed by mass spectrometry.
1
—
—